» Articles » PMID: 30884449

Low Susceptibility of Asunaprevir Towards R155K and D168A Point Mutations in HCV NS3/4A Protease: A Molecular Dynamics Simulation

Overview
Date 2019 Mar 19
PMID 30884449
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C has become an important health problem that requires expensive treatment and leads to liver tumorigenesis. Hepatitis C virus (HCV), which is the main cause of hepatitis C, has a high mutation rate due to the lack of proofreading activity of the RNA polymerase enzyme. The NS3/4A serine protease is an important target for anti-HCV drug discovery and development because of its crucial role in the cleavage of the polypeptides involved in viral replication. In the present study, all-atom molecular dynamics simulation was performed to elucidate the effect of the single point mutations R155K and D168A in the HCV genotype 1 NS3/4A protease on the structural dynamics, molecular interactions and susceptibility of asunaprevir (ASV), a second-generation NS3/4A protease inhibitor. Principal component analysis indicated that these two mutations converted the direction of motion of residues 123, 155 and 168 in the binding pocket to significantly point outwards from ASV, resulting in a loss of the hydrogen bond network of residues R123···R155···D168. The free energy calculations based on different semiempirical QM/MM-GBSA methods revealed that the binding affinity of ASV with the two mutant forms of the NS3/4A protease was significantly decreased in the order of wild-type < R155K < D168A. This work provided useful structural information regarding the atomistic understanding of acquired drug resistance against ASV caused by the R155K and D168A mutations.

Citing Articles

FMO-guided design of darunavir analogs as HIV-1 protease inhibitors.

Chuntakaruk H, Hengphasatporn K, Shigeta Y, Aonbangkhen C, Lee V, Khotavivattana T Sci Rep. 2024; 14(1):3639.

PMID: 38351065 PMC: 10864397. DOI: 10.1038/s41598-024-53940-1.


Exploring the interactions of antihistamine with retinoic acid receptor beta (RARB) by molecular dynamics simulations and genome-wide meta-analysis.

Kim M, Kulkarni V, Goode M, Sivesind T J Mol Graph Model. 2023; 124:108539.

PMID: 37331258 PMC: 10529808. DOI: 10.1016/j.jmgm.2023.108539.


Sulfonylated Indeno[1,2-]quinoline Derivatives as Potent EGFR Tyrosine Kinase Inhibitors.

Hengphasatporn K, Aiebchun T, Mahalapbutr P, Auepattanapong A, Khaikate O, Choowongkomon K ACS Omega. 2023; 8(22):19645-19655.

PMID: 37305292 PMC: 10249031. DOI: 10.1021/acsomega.3c01195.


Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases.

Sanachai K, Mahalapbutr P, Hengphasatporn K, Shigeta Y, Seetaha S, Tabtimmai L ACS Omega. 2022; 7(37):33548-33559.

PMID: 36157769 PMC: 9494641. DOI: 10.1021/acsomega.2c04535.


Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening.

Sanachai K, Somboon T, Wilasluck P, Deetanya P, Wolschann P, Langer T PLoS One. 2022; 17(6):e0269563.

PMID: 35771802 PMC: 9246117. DOI: 10.1371/journal.pone.0269563.